p73 G4C14-to-A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck

International Journal of Cancer

Volumn 125, Issue 11, 2009, Pages 2660-2665

  Li, Fanglin ^a,b   Sturgis, Erich M ^a   Zafereo, Mark E ^a,c   Liu, Zhensheng ^a   Wang, Li E ^a   Wei, Qingyi ^a   Li, Guojun ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b SHANDONG UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Genetic susceptibility; p73 G4C14 to A4T14; Polymorphism; Second primary malignancy; Squamous cell carcinoma of head and neck

Indexed keywords

PROTEIN P73; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CANCER SURVIVAL; CIGARETTE SMOKING; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECOND CANCER; SEX DIFFERENCE; COHORT ANALYSIS; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 70350708154     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24570     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Xu J, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Rennemo E, Zatterstrom U, Boysen M. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope 2008;118:1350-1356
3. Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Laringol Otol Rinol Faringol 1995;104:946-954
4. Day GL, Blot WJ, Shore RE, Mclaughlin JK, Austin DF, Greenberg RS, Liff JM, Preston-Martin S, Sarkar S, Schoenberg JB, Fraumeni JF. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 1994;86:131-137 (Pubitemid 24040152)
5. Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Spitz MR. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 2004;101:2837-2842
6. Ng AK, Travis LB. Second primary cancers: an overview. Hematol Oncol Clin North Am 2008;22:271-289
7. Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003;159:161-173
8. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ 1996;313:716-721
9. Jost CA, Marin MC, Kaelin WG, Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997;389:191-194
10. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, Mckeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-564
11. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI, Liu W. Activation of p73 silent allele in lung cancer. Cancer Res 1998;58:2347-2349 (Pubitemid 28252692)
12. Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S, Smith DI, Liu W. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 1999;18:1629-1633 (Pubitemid 29108063)
13. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998;58:2076-2077 (Pubitemid 28232887)
14. Nimura Y, Mihara M, Ichimiya S, Sakiyama S, Seki N, Ohira M, Nomura N, Fujimori M, Adachi W, Amano J, He M, Ping YM, et al. p73, a gene related to p53, is not mutated in esophageal carcinomas. Int J Cancer 1998;78:437-440 (Pubitemid 28481161)
15. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999;59:3257-3263 (Pubitemid 29316031)
16. Kang MJ, Park BJ, Byun DS, Park JI, Kim HJ, Park JH, Chi SG. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. Clin Cancer Res 2000;6:1767-1771
17. Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, Dunphy E, Mick R, Yandell D, Weichselbaum RR. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992;52:4832-4836
18. Bénard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003;21:182-191 (Pubitemid 36292961)
19. Gallo O, Bianchi S. p53 expression: a potential biomarker for risk of multiple primary malignancies in the upper aerodigestive tract. Eur J Cancer B Oral Oncol 1995;31:53-57
20. Homann N, Nees M, Conradt C, Dietz A, Weidauer H, Maier H, Bosch FX. Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin Cancer Res 2001;7:290-296 (Pubitemid 32183032)
21. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, Mckeon F, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-819 (Pubitemid 27357971)
22. Hu Z, Miao X, Ma H, Tan W, Wang X, Lu D, Wei Q, Lin D, Shen H. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer 2005;114:455-460 (Pubitemid 40279969)
23. Li G, Wang LE, Chamberlain RM, Amos CI, Spitz MR, Wei Q. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res 2004;64:6863-6866 (Pubitemid 39330992)
24. Li G, Sturgis EM, Wang LE, Chamberlain RM, Amos CI, Spitz MR, El-Naggar AK, Hong WK, Wei Q. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2004;25:1911-1916 (Pubitemid 39405910)
25. Ryan BM, Mcmanus R, Daly JS, Carton E, Keeling PW, Reynolds JV, Kelleher DA. Common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer 2001;85:1499-1503 (Pubitemid 34001580)
26. Niwa Y, Hamajima N, Atsuta Y, Yamamoto K, Tamakoshi A, Saito T, Hirose K, Nakanishi T, Nawa A, Kuzuya K, Tajima K. Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett 2004;205:55-60. (Pubitemid 38230139)
27. Pfeifer D, Arbman G, Sun XF. Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis 2005;26:103-107 (Pubitemid 40207704)
28. Chen K, Hu Z, Wang LE, Zhang W, El-Naggar AK, Sturgis EM, Wei Q. Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:4300-4305
29. Zhen SL, Calderon J, Zhang Z, Sturgis EM, Spitz MR, Wei Q. Polymorphisms of vitamin D receptor gene protect against risk of head and neck cancer. Pharmacogenet Genomics 2005;15:159-165 (Pubitemid 40569902)
30. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 1932;51:1358.
31. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T, Kato T, Tajima K, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002;181:81-85 (Pubitemid 34326437)
32. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 2000;10:307-311
33. Sun XF. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 2002;8:165-170 (Pubitemid 34101473)
34. Guan M, Peng HX, Yu B, Lu Y. p73 overexpression and angiogenesis in human colorectal carcinoma. Jpn J Clin Oncol 2003;33:215-220 (Pubitemid 43115261)
35. Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Fu KK, Spitz MR. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control 2003;14:131-138 (Pubitemid 36539519)
36. Hashibe M, Ritz B, Le AD, Li G, Sankaranarayanan R, Zhang ZF. Radiotherapy for oral cancer as a risk factor for second primary cancers. Cancer Lett 2005;220:185-195 (Pubitemid 40568776)
37. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194
38. Ko Y, Abel J, Harth V, Bröde P, Antony C, Donat S, Fischer HP, Ortiz-Pallardo ME, Thier R, Sachinidis A, Vetter H, Bolt HM, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398-4404
39. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004;10:1956-1962 (Pubitemid 38375553)